Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.
Blay JY, Chevret S, Le Cesne A, Brahmi M, Penel N, Cousin S, Bertucci F, Bompas E, Ryckewaert T, Soibinet P, Boudou-Rouquette P, Saada Bouzid E, Soulie P, Valentin T, Lotz JP, Tosi D, Neviere Z, Cancel M, Ray-Coquard I, Gambotti L, Legrand F, Lamrani-Ghaouti A, Simon C, Even C, Massard C. Blay JY, et al. Among authors: boudou rouquette p. Lancet Oncol. 2023 Aug;24(8):892-902. doi: 10.1016/S1470-2045(23)00282-6. Epub 2023 Jul 7. Lancet Oncol. 2023. PMID: 37429302 Clinical Trial.
Soluble VEGFR-1: a new biomarker of sorafenib-related hypertension (i.e., sorafenib-related is the compound adjective?).
Thomas-Schoemann A, Blanchet B, Boudou-Rouquette P, Golmard JL, Noé G, Chenevier-Gobeaux C, Lebbe C, Pages C, Durand JP, Alexandre J, Goldwasser F, Guibourdenche J, Vidal M. Thomas-Schoemann A, et al. J Clin Pharmacol. 2015 Apr;55(4):478-9. doi: 10.1002/jcph.429. Epub 2014 Dec 30. J Clin Pharmacol. 2015. PMID: 25401221 No abstract available.
Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study.
Boudou-Rouquette P, Narjoz C, Golmard JL, Thomas-Schoemann A, Mir O, Taieb F, Durand JP, Coriat R, Dauphin A, Vidal M, Tod M, Loriot MA, Goldwasser F, Blanchet B. Boudou-Rouquette P, et al. PLoS One. 2012;7(8):e42875. doi: 10.1371/journal.pone.0042875. Epub 2012 Aug 13. PLoS One. 2012. PMID: 22912756 Free PMC article.
Metastatic fractures of long limb bones.
Anract P, Biau D, Boudou-Rouquette P. Anract P, et al. Orthop Traumatol Surg Res. 2017 Feb;103(1S):S41-S51. doi: 10.1016/j.otsr.2016.11.001. Epub 2017 Jan 11. Orthop Traumatol Surg Res. 2017. PMID: 28089230 Free article. Review.
Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib.
Tlemsani C, Huillard O, Arrondeau J, Boudou-Rouquette P, Cessot A, Blanchet B, Thomas-Schoemann A, Coriat R, Durand JP, Giroux J, Alexandre J, Goldwasser F. Tlemsani C, et al. Expert Opin Drug Metab Toxicol. 2015 May;11(5):785-94. doi: 10.1517/17425255.2015.1030392. Epub 2015 Mar 25. Expert Opin Drug Metab Toxicol. 2015. PMID: 25809423 Review.
Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.
Narjoz C, Cessot A, Thomas-Schoemann A, Golmard JL, Huillard O, Boudou-Rouquette P, Behouche A, Taieb F, Durand JP, Dauphin A, Coriat R, Vidal M, Tod M, Alexandre J, Loriot MA, Goldwasser F, Blanchet B. Narjoz C, et al. Invest New Drugs. 2015 Feb;33(1):257-68. doi: 10.1007/s10637-014-0178-2. Epub 2014 Oct 25. Invest New Drugs. 2015. PMID: 25344452 Clinical Trial.
120 results